The board of directors of Shanghai Junshi Biosciences Co., Ltd. announced that, the Company has received the Clinical Trial Approval issued by the National Medical Products Administration (NMPA). The investigational new drug application for JS006 Injection (product code: JS006) has been approved. Relevant information is as follows: Drug name: JS006 Injection. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after the review, JS006 Injection accepted for application on 22 November 2020 fulfils the relevant requirements regarding drug registration and is approved to conduct clinical trials. JS006 is a specific anti-TIGIT monoclonal antibody injection developed independently by the Company. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR inhibitory pathway, meanwhile, it can stimulate the activation of killing immune cell to secrete tumor-killing factors. TIGIT (T cell immunoglobulin and ITIM domain) is an emerging inhibitory receptor shared by NK cells and T cells, which can bind to PVR receptors highly expressed on tumor cells to mediate inhibitory signals of immune responses, thereby directly inhibiting the killing effect of NK cells and T cells on tumor cells. The effect is similar to the inhibitory effect of PD-1 on T cells. A number of pre-clinical trial results showed that anti-TIGIT antibody and anti-PD-1/PD-L1 antibody can play a synergistic antitumor effect. The combination of the two is a promising antitumor treatment strategy, which is expected to increase patients' response to immunotherapy and expand the range of potential beneficiaries. Currently, there are no products with similar targets approved for marketing domestically and overseas.